20 articles
UC Davis scientists created novel brain-healing molecules that activate key serotonin receptors tied to neuroplasticity — without triggering hallucinations.
Researchers created modified psilocin that maintains antidepressant effects while dramatically reducing psychedelic side effects in mice.
A study of 100,000 people found semaglutide users had 44% lower depression risk and 42% fewer psychiatric hospitalizations.
A 12-week clinical trial found older adults taking probiotics with antidepressants had greater reductions in depression and anxiety than placebo.
New research reveals GLP-1 drugs like Ozempic significantly reduce depression, anxiety, and substance use disorders alongside weight management.
Scientists used advanced brain imaging to reveal how ketamine reshapes key receptors in specific brain regions to quickly lift severe depression.
Arginine supplements reduced toxic amyloid buildup, brain inflammation, and behavioral decline in fly and mouse Alzheimer's models.
New compounds targeting the cPLA2 enzyme may reduce Alzheimer's-linked brain inflammation, especially in high-risk APOE4 gene carriers.
A Cochrane review of 20,000+ patients finds amyloid-clearing drugs offer no meaningful benefit and raise brain bleed and swelling risks.
Researchers finally discovered lecanemab activates brain immune cells through a specific antibody fragment to clear toxic plaques.
Clinical trial shows solriamfetol significantly improves alertness and performance in workers who start before sunrise.
Researchers finally discovered how lecanemab clears brain plaques by activating immune cells through a specific antibody fragment.
Buck Institute finds the longevity-linked APOE2 variant shields neurons from DNA damage and cellular senescence, explaining its Alzheimer's protection.
Blocking the protein PTP1B boosted memory and cleared brain plaque in mice, with potential links to diabetes and obesity treatment.
UK study of 165,000 dementia patients finds risperidone increases stroke risk across all groups, challenging safety assumptions.
A large clinical trial finds baduanjin, a gentle 800-year-old Chinese practice, lowers blood pressure comparably to medication and brisk walking.
A Rutgers study finds GLP-1 users show dramatically weaker links between impulsivity, alcohol use, and violent behavior.
UK study of 165,000 dementia patients finds risperidone increases stroke risk across all groups, challenging safety assumptions.
New NIH research reveals the brain-cell signaling mechanism behind GLP-1 drug plateaus and a potential way to extend their effects.
A home-based walking and resistance program improved attention and reduced observable cognitive decline in chemotherapy patients over 6 weeks.
